QUICK ANSWER · AEO / GEO
A synthetic immunomodulatory peptide with jurisdiction-specific medicine status and indication-bounded clinical evidence.
ENTITY FACTS
What should readers identify first?
What remains unknown?
- which biomarker-defined subgroups, if any, derive clinically meaningful benefit
- comparative benefit against current standard-of-care therapies for each indication
- long-term safety in autoimmune, transplant and oncology populations
- equivalence of free base, acetate and marketed/compounded formulations
- quality and immunogenicity of product-specific compounded preparations
- current Thai marketing-authorisation status
What limits these conclusions?
- The evidence spans different indications, eras, background therapies, formulations and jurisdictions. Many positive studies are small, single-blind, observational or use outdated comparators. The most rigorous recent sepsis trial was negative. FDA found insufficient effectiveness across the nominated compounding uses and substantial product-characterization and safety gaps; foreign approval cannot be generalized beyond its label.
This overview does not replace the detailed adverse-event and product-specific risk discussion in the complete Thai profile or the original sources.
EVIDENCE BOUNDARY
What this overview does not establish
- An evidence grade does not rank this molecule against another treatment.
- A molecule name does not establish the identity, purity or regulatory status of a product.
- Animal, cell or biomarker findings do not automatically establish human clinical benefit.
- Approval in one country or indication does not transfer globally.
Where can I check the evidence?
Original sources from the same evidence record used by Compare. Read each source's population, methods, limitations and date; a citation is not product endorsement.
- https://medicinali.aifa.gov.it/it/#/it/dettaglio/0000022315
- https://www.drugoffice.gov.hk/eps/drug/productDetail2/en/consumer/155704
- https://cdsco.gov.in/opencms/resources/UploadCDSCOWeb/2018/UploadCommitteeFiles/Recommendations%20Antimicrobial%20%26%20Antiviral%20dated%2009.05.2024.pdf
- https://cdsco.gov.in/opencms/resources/UploadCDSCOWeb/2018/UploadApprovalMarketingFDC/sndapprovjuly.pdf
- https://www.fda.gov/media/183820/download
- https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
- https://pubmed.ncbi.nlm.nih.gov/39814420/
- https://clinicaltrials.gov/study/NCT02867267
- https://pubmed.ncbi.nlm.nih.gov/23327199/
- https://clinicaltrials.gov/study/NCT00711620
- https://pubmed.ncbi.nlm.nih.gov/40969554/
- https://www.wada-ama.org/en/resources/world-anti-doping-program/prohibited-list
- https://products.mhra.gov.uk/
FAQ · ANSWER ENGINE
Frequently asked questions
What is Thymosin Alpha-1?
Thymosin Alpha-1 is described pharmacologically as Synthetic N-terminal acetylated 28-amino-acid immunomodulatory peptide. A synthetic immunomodulatory peptide with jurisdiction-specific medicine status and indication-bounded clinical evidence.
Does Thymosin Alpha-1 have strong evidence?
PrimeCoreBio records Evidence Grade B. This grade describes evidence strength, not comparative effectiveness or suitability for an individual.
Is Thymosin Alpha-1 approved everywhere?
No global conclusion should be inferred. PrimeCore Class A must be read with the exact product, country and indication on the source-rich profile.
Educational information only. This page does not provide diagnosis, treatment, prescribing, dosage, injection instructions or individual medical advice.